{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:06:29Z","timestamp":1763762789041,"version":"3.45.0"},"reference-count":12,"publisher":"The Pediatric Pharmacy Association","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec id=\"st1\">\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Monoclonal antibody therapy has been used to treat COVID-19, with paucity of literature about its use in children. This retrospective study sought to evaluate the effectiveness of preventing hospitalization and safety of monoclonal antibody (mAb) treatment (bamlanivimab-etesevimab and casirivimab-imdevimab) for COVID-19 in patients \u226418 years of age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"st2\">\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      Between January 1 and December 31, 2021, patients were selected for mAb therapy, based on the referring provider\u2019s clinical assessment of high risk for progression to severe COVID-19. The choice of mAb was determined by drug availability, compounding feasibility, and documented\n                      <jats:italic>in vitro<\/jats:italic>\n                      activity against circulating SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) variants. All patients received a single-dose infusion. Primary outcomes included hospital readmissions and emergency department (ED) visits within 90 days of treatment. The secondary outcome was safety\/adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"st3\">\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Of 141 patients who received mAbs in 2021, only 3 experienced ongoing COVID-19 symptoms. Only 1 patient necessitated escalated care owing to persistent COVID-19 symptoms post infusion. There were no infusion-related side effects or hospitalizations in the 90 days post infusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"st4\">\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Monoclonal antibodies appear to be safe and effective in preventing hospitalizations in COVID-19\u2013positive children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5863\/jppt-24-00095","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:03:34Z","timestamp":1763762614000},"page":"655-659","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and Safety of Outpatient Monoclonal Antibody Use for the Treatment of COVID-19 in Children and Adolescents: Single Center Study"],"prefix":"10.5863","volume":"30","author":[{"given":"Julia","family":"Cheng","sequence":"first","affiliation":[{"name":"University of South Florida Morsani College of Medicine (JC, EH), Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Heideman","sequence":"additional","affiliation":[{"name":"University of South Florida Morsani College of Medicine (JC, EH), Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Espinosa","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Diseases (CE, CG-A), University of South Florida Morsani College of Medicine, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Zeitler","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (NP, KZ), Tampa General Hospital, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Piccicacco","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (NP, KZ), Tampa General Hospital, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Gaviria-Agudelo","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Diseases (CE, CG-A), University of South Florida Morsani College of Medicine, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"6","key":"i2331-348X-30-5-655-b01","series-title":"Nat Rev Immunol","first-page":"382","article-title":"Neutralizing monoclonal antibodies for treatment of COVID-19","volume":"21","author":"Taylor","year":"2021","unstructured":"Taylor PC, Adams AC, Hufford MM, et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382\u2013393."},{"issue":"4","key":"i2331-348X-30-5-655-b02","series-title":"Open Forum Infect Dis","first-page":"ofac080","article-title":"Comparative efficacy of early COVID-19 monoclonal antibody therapies: a retrospective analysis","volume":"14","author":"San Filippo","year":"2022","unstructured":"San Filippo S, Crovetto B, Bucek J, et al. Comparative efficacy of early COVID-19 monoclonal antibody therapies: a retrospective analysis. Open Forum Infect Dis. 2022;14(4):ofac080."},{"key":"i2331-348X-30-5-655-b03","series-title":"Bamlanivimab","article-title":"StatPearls [serial online]","author":"Shrestha","year":"2023","unstructured":"Shrestha J, Sherchan R. Bamlanivimab. In: StatPearls [serial online]. Treasure Island, FL: StatPearls Publishing. January 2023. Accessed April 15, 2022. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK576376\/#"},{"issue":"15","key":"i2331-348X-30-5-655-b04","series-title":"N Engl J Med","first-page":"1382","article-title":"Bamlanivimab plus etesevimab in mild or moderate Covid-19","volume":"385","author":"Dougan","year":"2021","unstructured":"Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med. 2021;385(15):1382\u20131392."},{"issue":"5","key":"i2331-348X-30-5-655-b05","series-title":"J Pediatr Infect Dis Soc","first-page":"177","article-title":"Updated guidance on use and prioritization of monoclonal antibody therapy for treatment of COVID-19 in adolescents","volume":"11","author":"Wolf","year":"2022","unstructured":"Wolf J, Abzug MJ, Anosike BI, et al. Updated guidance on use and prioritization of monoclonal antibody therapy for treatment of COVID-19 in adolescents. J Pediatr Infect Dis Soc. 2022;11(5)177\u2013185."},{"issue":"10325","key":"i2331-348X-30-5-655-b06","series-title":"Lancet","first-page":"665","article-title":"Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","year":"2022","unstructured":"Recovery Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022;399(10325):665\u2013676."},{"issue":"3","key":"i2331-348X-30-5-655-b07","series-title":"N Engl J Med","first-page":"238","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","unstructured":"Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384(3):238\u2013251."},{"key":"i2331-348X-30-5-655-b08","article-title":"COVID-19","unstructured":"Centers for Disease Control and Prevention. COVID-19. Accessed September 12, 2022. https:\/\/www.cdc.gov\/covid\/hcp\/clinical-care\/for-pediatric-hcp.html"},{"issue":"1","key":"i2331-348X-30-5-655-b09","series-title":"Int J Emerg Med","first-page":"9","article-title":"The use of monoclonal antibody therapy in pediatric patients with COVID-19: a retrospective case series","volume":"15","author":"Santos","year":"2022","unstructured":"Santos JL, Bhisitkul D, Carman M, et al. The use of monoclonal antibody therapy in pediatric patients with COVID-19: a retrospective case series. Int J Emerg Med. 2022;15(1):9."},{"issue":"12","key":"i2331-348X-30-5-655-b10","series-title":"Pediatr Infect Dis J","first-page":"985","article-title":"Single site experience of the use of monoclonal antibodies for the treatment of COVID-19 in high-risk pediatric and young adult patients","volume":"41","author":"Bahakel","year":"2022","unstructured":"Bahakel H, Murphy C, Frenck RW, et al. Single site experience of the use of monoclonal antibodies for the treatment of COVID-19 in high-risk pediatric and young adult patients. Pediatr Infect Dis J. 2022;41(12):985\u2013988."},{"issue":"3","key":"i2331-348X-30-5-655-b11","series-title":"J Pediatr Infect Dis Soc","first-page":"152","article-title":"Monoclonal antibody use for coronavirus disease 2019 in pediatric patients: a multicenter retrospective study","volume":"12","author":"Sherman","year":"2023","unstructured":"Sherman G, Lamb GS, Sharma TS, et al. Monoclonal antibody use for coronavirus disease 2019 in pediatric patients: a multicenter retrospective study. J Pediatr Infect Dis Soc. 2023;12(3):152\u2013155."},{"issue":"12","key":"i2331-348X-30-5-655-b12","series-title":"J Pediatr Infect Dis Soc","first-page":"565","article-title":"Implementation and patient outcomes of a pediatric COVID-19 monoclonal antibody program","volume":"11","author":"Blind","year":"2022","unstructured":"Blind JE, Sapko M, Killough A, et al. Implementation and patient outcomes of a pediatric COVID-19 monoclonal antibody program. J Pediatr Infect Dis Soc. 2022;11(12):565\u2013574."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/30\/5\/article-p655.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/30\/5\/article-p655.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/30\/5\/article-p655.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:03:34Z","timestamp":1763762614000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/30\/5\/article-p655.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":12,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.5863\/jppt-24-00095","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}